Recursion Pharmaceuticals to spotlight self-driving lab model at NVIDIA GTC 2026
Recursion Pharmaceuticals spotlights its self-driving lab model at NVIDIA GTC 2026. Explore what this means for AI drug discovery and regulation.
Lilly and NVIDIA commit $1bn to AI co-innovation lab for next-gen drug discovery
Eli Lilly and Company and NVIDIA have announced the formation of a co-innovation lab aimed at accelerating drug discovery using AI, robotics, and advanced compute. With a planned $1 billion investment over five years, the lab will leverage NVIDIA’s BioNeMo platform and Vera Rubin architecture alongside Lilly’s drug development expertise. The initiative represents one of […]